Achieve Life Sciences (ACHV) EBITDA (2010 - 2018)
Achieve Life Sciences' (ACHV) quarterly EBITDA came in at $43.5 million in Q4 2018, up 1344.59% YoY from $3.0 million in Q4 2017, and up 2486.72% on a QoQ basis from -$1.8 million in Q3 2018.
Achieve Life Sciences (ACHV) EBITDA (2010 - 2018) Analysis & Trends
Achieve Life Sciences (ACHV) has 7 years of EBITDA data on file, last reported at $43.5 million in Q4 2018.
- Quarterly EBITDA rose 1344.59% year-over-year to $43.5 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $38.7 million (up 12.96% YoY) and the FY2019 annual result came in at -$16.2 million, down 147.1% from the prior year.
- EBITDA advanced to $43.5 million in Q4 2018, from -$1.8 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $45.7 million in Q1 2017 to a low of -$7.8 million in Q3 2017.
- A 4-year average of $6.4 million and a median of -$1.2 million in 2015 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2017 — EBITDA tumbled 2444.26% — and 2018, when it surged 1344.59%.
- Tracing ACHV's EBITDA over 4 years: stood at -$1.2 million in 2015, then surged by 53.75% to -$567000.0 in 2016, then slumped by 516.23% to -$3.5 million in 2017, then surged by 1344.59% to $43.5 million in 2018.
- The last three EBITDA figures came in at $43.5 million (Q4 2018), -$1.8 million (Q3 2018), and -$1.4 million (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 43.49 Mn |
| Sep 30, 2018 | -1.82 Mn |
| Jun 30, 2018 | -1.37 Mn |
| Mar 31, 2018 | -1.60 Mn |
| Dec 31, 2017 | -3.49 Mn |
| Sep 30, 2017 | -7.76 Mn |
| Jun 30, 2017 | -166,000.00 |
| Mar 31, 2017 | 45.67 Mn |
| Dec 31, 2016 | -567,000.00 |
| Sep 30, 2016 | -305,000.00 |
| Dec 31, 2015 | -1.23 Mn |
| Dec 31, 2012 | 35.52 Mn |
| Sep 30, 2012 | 8.29 Mn |
| Jun 30, 2012 | 5.94 Mn |
| Mar 31, 2012 | -5.50 Mn |
| Dec 31, 2011 | -86.68 Mn |
| Sep 30, 2011 | 4.10 Mn |
| Jun 30, 2011 | 4.99 Mn |
| Mar 31, 2011 | -5.23 Mn |
| Dec 31, 2010 | -2.80 Mn |